This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
MO Expands Smoke-Free Portfolio: Can It Offset Combustible Declines?
by Zacks Equity Research
Altria's on! nicotine pouch shipments surge 26.5% in the second quarter, but can smoke-free gains offset cigarette declines?
Turning Point Brands (TPB) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Turning Point Brands (TPB) delivered earnings and revenue surprises of +24.05% and +10.50%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
VEEV Volumes Double: Will Philip Morris' E-Vapor Bet Pay Off?
by Swati Prasad
PM's VEEV shipments have more than doubled in the second quarter, with Europe driving growth and new markets showing early promise.
Can ZYN and IQOS Sustain Philip Morris' Smoke-Free Surge?
by Zacks Equity Research
IQOS and ZYN power PM's smoke-free growth in Q2, now accounting for more than 40% of revenues and gross profit.
Will Strong Pricing Power Offset Altria's Volume Declines in 2025?
by Zacks Equity Research
Altria leans on strong pricing and Marlboro's brand power to offset a drop in cigarette volumes in the second quarter.
Altria (MO) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Altria (MO) delivered earnings and revenue surprises of +5.11% and +1.93%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Altria's Q2 Earnings on the Deck: How to Play the Stock
by Swati Prasad
MO's Q2 results are likely to reflect NJOY ACE's market exit and soft cigarette volumes, though pricing strength may help.
Here's Why Philip Morris Raises Its 2025 EPS Guidance Again
by Zacks Equity Research
PM hikes its 2025 EPS guidance as smoke-free products like IQOS and ZYN boost the second-quarter performance.
Is on! the Bright Spot in Altria's Oral Tobacco Portfolio?
by Zacks Equity Research
With rising brand loyalty and expanding reach, on! is reshaping MO's future in the oral nicotine space.
Philip Morris (PM) Q2 Earnings Top Estimates
by Zacks Equity Research
Philip Morris (PM) delivered earnings and revenue surprises of +3.24% and -1.12%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Should Philip Morris Stock Be in Your Portfolio Ahead of Q2 Earnings?
by Swati Prasad
PM's second quarter results are likely to benefit from strong pricing and sustained smoke-free momentum despite currency pressures.
Turning Point Brands (TPB) Soars 5.1%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Turning Point Brands (TPB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Behind Altria's Profit Resilience: The Power of Pricing Strategy
by Ansuiya Mohta
MO leans on pricing power to lift profits, offsetting cigarette volume drops and regulatory headwinds.
Is Philip Morris' Pricing Power Behind Its Profit Strength?
by Swati Prasad
PM's strong pricing and premium product mix fuel profit growth and margin gains in the nicotine category.
Altria Group Gains 21% in 6 Months: How to Play the Stock?
by Swati Prasad
MO is gaining ground with strong Marlboro pricing, smoke-free growth, and solid value, appealing to income-focused investors.
Philip Morris Gains 21% in 3 Months: How to Play the Stock?
by Swati Prasad
PM is gaining ground with smoke-free products and cost cuts, but regulatory and currency risks call for caution.
MO Strengthens on! Brand: Can it Sustain Momentum in Nicotine Pouches?
by Swati Prasad
Altria gains ground in smoke-free with on! pouches, lifting market share and boosting awareness through bold marketing moves.
PM Grows Smoke-Free Profit Share: Will Margins Keep Expanding?
by Swati Prasad
Philip Morris' smoke-free shift gained momentum in the first quarter of 2025 as high-margin products drove profit growth and strengthened its portfolio mix.
Top 3 Tobacco Stocks to Watch Amid Strong Industry Growth Trends
by Ansuiya Mohta
PM, MO and TPB are riding a wave of RRP innovation and pricing power as the tobacco industry pivots toward smoke-free growth.
Can Philip Morris Rely on Pricing to Drive 2025 EPS Growth?
by Zacks Equity Research
PM lifts its 2025 EPS forecast after a strong first quarter, but can pricing alone keep driving growth through year-end?
Altria Trades at a Bargain: Is it a Good Time to Buy the Stock?
by Ansuiya Mohta
MO trades at a steep discount to peers and shows bullish momentum, making it a potential value play in tobacco's shift to smoke-free.
Philip Morris Stock Records 50% YTD Surge: Is it Too Late to Buy?
by Ansuiya Mohta
PM stock soars 50.1% year to date, fueled by smoke-free growth, premium pricing and bullish earnings momentum.
Is Altria's Post Q1 Earnings Stock Dip a Green Light for Investors?
by Ansuiya Mohta
MO is backed by strong fundamentals, pricing power and long-term growth potential in smoke-free products.
PM Stock Up 6.9% Post Q1 Earnings: A Green Light for Investors?
by Ansuiya Mohta
PM shows strong growth prospects, driven by its successful shift to smoke-free products, solid first-quarter results and optimistic guidance.
Turning Point Brands (TPB) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Turning Point Brands (TPB) delivered earnings and revenue surprises of 21.33% and 11.92%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?